Triple-negative breast cancer: treatment challenges and solutions

Joëlle Collignon,1 Laurence Lousberg,1 Hélène Schroeder,1 Guy Jerusalem,1,21Medical Oncology Department, CHU Sart Tilman Liege, Domaine Universitaire du Sart Tilman, Liege, Belgium; 2University of Liege, Liege, Belgium Abstract: Triple-negative breast cancers (TNBCs)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Collignon J, Lousberg L, Schroeder H, Jerusalem G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	triple-negative breast cancer molecular subtype platinum-based chemotherapy targeted therapy androgen receptor BRCA1/2 mutation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/6ecac533efc24ac0abbdd42f4341e1ca
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6ecac533efc24ac0abbdd42f4341e1ca
record_format	dspace
spelling	oai:doaj.org-article:6ecac533efc24ac0abbdd42f4341e1ca2021-12-02T06:10:07ZTriple-negative breast cancer: treatment challenges and solutions1179-1314https://doaj.org/article/6ecac533efc24ac0abbdd42f4341e1ca2016-05-01T00:00:00Zhttps://www.dovepress.com/triple-negative-breast-cancer-treatment-challenges-and-solutions-peer-reviewed-article-BCTThttps://doaj.org/toc/1179-1314Joëlle Collignon,1 Laurence Lousberg,1 Hélène Schroeder,1 Guy Jerusalem,1,21Medical Oncology Department, CHU Sart Tilman Liege, Domaine Universitaire du Sart Tilman, Liege, Belgium; 2University of Liege, Liege, Belgium Abstract: Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and progesterone receptors and the absence of HER2 overexpression. These cancers represent a heterogeneous breast cancer subtype with a poor prognosis. Few systemic treatment options exist besides the use of chemotherapy (CT). The heterogeneity of the disease has limited the successful development of targeted therapy in unselected patient populations. Currently, there are no approved targeted therapies for TNBC. However, intense research is ongoing to identify specific targets and develop additional and better systemic treatment options. Standard adjuvant and neoadjuvant regimens include anthracyclines, cyclophosphamide, and taxanes. Platinum-based CT has been proposed as another CT option of interest in TNBC. We review the role of this therapy in general, and particularly in patients carrying BRCA germ-line mutations. Available data concerning the role of platinum-based CT in TNBC were acquired primarily in the neoadjuvant setting. The routine use of platinum-based CT is not yet recommended by available guidelines. Many studies have reported the molecular characterization of TNBCs. Several actionable targets have been identified. Novel therapeutic strategies are currently being tested in clinical trials based on promising results observed in preclinical studies. These targets include androgen receptor, EGFR, PARP, FGFR, and the angiogenic pathway. We review the recent data on experimental drugs in this field. We also discuss the recent data concerning immunologic checkpoint inhibitors. Keywords: triple-negative breast cancer, molecular subtype, platinum-based chemotherapy, targeted therapy, androgen receptor, BRCA1/2 mutationCollignon JLousberg LSchroeder HJerusalem GDove Medical Pressarticletriple-negative breast cancermolecular subtypeplatinum-based chemotherapytargeted therapyandrogen receptorBRCA1/2 mutationNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENBreast Cancer: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 93-107 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	triple-negative breast cancer molecular subtype platinum-based chemotherapy targeted therapy androgen receptor BRCA1/2 mutation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	triple-negative breast cancer molecular subtype platinum-based chemotherapy targeted therapy androgen receptor BRCA1/2 mutation Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Collignon J Lousberg L Schroeder H Jerusalem G Triple-negative breast cancer: treatment challenges and solutions
description	Joëlle Collignon,1 Laurence Lousberg,1 Hélène Schroeder,1 Guy Jerusalem,1,21Medical Oncology Department, CHU Sart Tilman Liege, Domaine Universitaire du Sart Tilman, Liege, Belgium; 2University of Liege, Liege, Belgium Abstract: Triple-negative breast cancers (TNBCs) are defined by the absence of estrogen and progesterone receptors and the absence of HER2 overexpression. These cancers represent a heterogeneous breast cancer subtype with a poor prognosis. Few systemic treatment options exist besides the use of chemotherapy (CT). The heterogeneity of the disease has limited the successful development of targeted therapy in unselected patient populations. Currently, there are no approved targeted therapies for TNBC. However, intense research is ongoing to identify specific targets and develop additional and better systemic treatment options. Standard adjuvant and neoadjuvant regimens include anthracyclines, cyclophosphamide, and taxanes. Platinum-based CT has been proposed as another CT option of interest in TNBC. We review the role of this therapy in general, and particularly in patients carrying BRCA germ-line mutations. Available data concerning the role of platinum-based CT in TNBC were acquired primarily in the neoadjuvant setting. The routine use of platinum-based CT is not yet recommended by available guidelines. Many studies have reported the molecular characterization of TNBCs. Several actionable targets have been identified. Novel therapeutic strategies are currently being tested in clinical trials based on promising results observed in preclinical studies. These targets include androgen receptor, EGFR, PARP, FGFR, and the angiogenic pathway. We review the recent data on experimental drugs in this field. We also discuss the recent data concerning immunologic checkpoint inhibitors. Keywords: triple-negative breast cancer, molecular subtype, platinum-based chemotherapy, targeted therapy, androgen receptor, BRCA1/2 mutation
format	article
author	Collignon J Lousberg L Schroeder H Jerusalem G
author_facet	Collignon J Lousberg L Schroeder H Jerusalem G
author_sort	Collignon J
title	Triple-negative breast cancer: treatment challenges and solutions
title_short	Triple-negative breast cancer: treatment challenges and solutions
title_full	Triple-negative breast cancer: treatment challenges and solutions
title_fullStr	Triple-negative breast cancer: treatment challenges and solutions
title_full_unstemmed	Triple-negative breast cancer: treatment challenges and solutions
title_sort	triple-negative breast cancer: treatment challenges and solutions
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/6ecac533efc24ac0abbdd42f4341e1ca
work_keys_str_mv	AT collignonj triplenegativebreastcancertreatmentchallengesandsolutions AT lousbergl triplenegativebreastcancertreatmentchallengesandsolutions AT schroederh triplenegativebreastcancertreatmentchallengesandsolutions AT jerusalemg triplenegativebreastcancertreatmentchallengesandsolutions
_version_	1718400056984338432

Triple-negative breast cancer: treatment challenges and solutions

Ejemplares similares